Cohort analysis reports progression-free and overall survival differences in advanced NSCLC, highlighting variable KRAS G12C inhibitor efficacy.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Negrão et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: